O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
-12.53%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$9.47B
AUM Growth
+$9.47B
(-14%)
Cap. Flow
+$164M
Cap. Flow
% of AUM
1.74%
Top 10 Holdings %
Top 10 Hldgs %
41.65%
Holding
145
New
14
Increased
43
Reduced
27
Closed
6
Top Buys
| 1 |
Vertex Pharmaceuticals
VRTX
|
$95.1M |
| 2 |
Corvus Pharmaceuticals
CRVS
|
$76.2M |
| 3 |
UnitedHealth
UNH
|
$74M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$72.1M |
| 5 |
Eli Lilly
LLY
|
$66.8M |
Top Sells
| 1 |
HNT
HEALTH NET INC
HNT
|
$205M |
| 2 |
Viatris
VTRS
|
$143M |
| 3 |
AFFX
AFFYMETRIX INC
AFFX
|
$75.8M |
| 4 |
ALXN
Alexion Pharmaceuticals Inc
ALXN
|
$56.3M |
| 5 |
Bristol-Myers Squibb
BMY
|
$49.2M |
Sector Composition
| 1 | Healthcare | 90.2% |
| 2 | Financials | 0.22% |
| 3 | Technology | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BXLT
76
DELISTED
BAXALTA INC COM STK (DE)
BXLT
| $13.2M | 0.14% |
326,000
+41,000
| +14% | +$1.66M |
|
77
Exact Sciences
EXAS
$8.98B
| $12.7M | 0.13% |
+1,890,400
| New | +$12.7M |
|
|
CLVS
78
DELISTED
Clovis Oncology, Inc.
CLVS
| $12.7M | 0.13% |
660,900
-68,700
| -9% | -$1.32M |
|
79
eHealth
EHTH
$118M
| $12.2M | 0.13% |
1,300,000
| – | – |
|
80
Natera
NTRA
$23.1B
| $12.1M | 0.13% |
1,276,190
| – | – |
|
81
McKesson
MCK
$85.4B
| $12.1M | 0.13% |
77,200
-272,172
| -78% | -$42.8M |
|
|
NBRV
82
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
| $11.8M | 0.12% |
1,315,000
| – | – |
|
83
Jazz Pharmaceuticals
JAZZ
$7.75B
| $11.8M | 0.12% |
90,000
| – | – |
|
84
The Ensign Group
ENSG
$9.91B
| $11.6M | 0.12% |
514,200
+19,000
| +4% | +$430K |
|
85
ProQR Therapeutics
PRQR
$237M
| $11.3M | 0.12% |
2,305,446
+33,946
| +1% | +$166K |
|
86
Merck
MRK
$210B
| $11.1M | 0.12% |
+210,400
| New | +$11.1M |
|
87
Zimmer Biomet
ZBH
$21B
| $11M | 0.12% |
103,000
-43,800
| -30% | -$4.67M |
|
|
SRRA
88
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $10.9M | 0.12% |
1,623,149
-366,800
| -18% | -$2.47M |
|
89
Rocket Pharmaceuticals
RCKT
$354M
| $10.3M | 0.11% |
1,391,000
+966,000
| +227% | +$7.15M |
|
90
Edwards Lifesciences
EW
$47.8B
| $10.1M | 0.11% |
+115,000
| New | +$10.1M |
|
91
Syndax Pharmaceuticals
SNDX
$1.41B
| $10.1M | 0.11% |
+757,365
| New | +$10.1M |
|
92
Abbott
ABT
$231B
| $9.91M | 0.1% |
237,000
+26,000
| +12% | +$1.09M |
|
|
CLLS
93
Cellectis
CLLS
$258M
| $9.63M | 0.1% |
350,000
| – | – |
|
94
Galapagos
GLPG
$2.07B
| $9.62M | 0.1% |
230,000
| – | – |
|
|
IMMU
95
DELISTED
Immunomedics Inc
IMMU
| $9.51M | 0.1% |
3,802,000
| – | – |
|
|
SIEN
96
DELISTED
Sientra, Inc.
SIEN
| $9.29M | 0.1% |
1,357,500
| – | – |
|
|
AET
97
DELISTED
Aetna Inc
AET
| $8.54M | 0.09% |
76,000
+9,000
| +13% | +$1.01M |
|
|
ITCI
98
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $8.17M | 0.09% |
+294,000
| New | +$8.17M |
|
99
Ultragenyx Pharmaceutical
RARE
$2.89B
| $8.12M | 0.09% |
+128,300
| New | +$8.12M |
|
100
Enanta Pharmaceuticals
ENTA
$180M
| $7.33M | 0.08% |
249,400
-254,900
| -51% | -$7.49M |
|